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. . . this kind of
information will
improve quality of
care and efficiency,
and if done well,
will lower costs. It
is essential that cost
does not become the
principle focus of
CER. Application
of comparative ef-
fectiveness data
should be through
guidelines and
practice standards
that are carefully
reviewed by a com-
mittee of peers to be
certain that the
information is ap-
plied appropriately.he raging debate on health care reform involves, among other things, a new
topic called “comparative effectiveness.” The American Recovery and Reinvest-
ment Act of 2009 invested $1.1 billion in comparative effectiveness research
CER), indicating that there are a number of people in government who think that this
ffort will have a significant impact on medical practice.
The original discussions about comparative effectiveness revolved around reducing cost
y examining various medical therapies and tests to determine which produced the low-
st cost while preserving the same outcome in care. This approach has often been used
n evaluating consumer goods to determine which provide the best value for the cost.
his idea is not lost on spending for medical care. The reason for the studies was obvi-
usly to lower health care costs, but it quickly became apparent that using cost as the
asis for selecting the value of a therapy or test could compromise quality of care. This
s particularly true because of the wide variation in patients based on age, ethnicity, sex,
nd so on, where one therapy might be the best for one type of patient, but not for oth-
rs. A number of organizations, including the American College of Cardiology, devel-
ped principles for CER (1) and stated clearly that comparisons of various therapies or
ests would be appropriate, but only if measures of clinical value were used as compara-
ors. The organizations that are tasked with reviewing the research proposals and distrib-
ting the funds (National Institutes of Health, Agency for Healthcare Research and
uality) are cognizant of the difference between a cost-based study and a clinically-based
tudy and are prepared to fund CER in a wide variety of topics.
To identify relevant topics, the Institute of Medicine assembled a group of experts in
ealth care to develop a list of priorities for CER (2). In it, they listed the first 100 top-
cs in 4 quartiles of priority. Cardiovascular disease is listed as a high priority for CER.
he highest quartile includes atrial fibrillation as the only cardiology-related comparative
ffectiveness question in need of urgent research funds. The specific comparison recom-
ended for comparative effectiveness was between medical therapy for atrial fibrillation
nd ablation therapy. This is indeed an unanswered question in cardiology practice, and
well-designed study that identified those patients who would benefit most from abla-
ion would be welcome information. Although we do not have direct comparisons under
he rubric of comparative effectiveness, many of the clinical trials that provide the basis
or guidelines and practice standards in fact compare various therapies or tests and pro-
ide guidance on the relative clinical value of the therapies or tests being discussed.
ost, however, has not been a part of guideline development, and it is likely that future
uidelines will provide some discussion of cost as well as relative efficacy when discussing
reatments or tests. Because the effectiveness of our therapies, and to some extent cost, is
ncorporated into all of our clinical decisions, having real data on many of these choices
hould improve care.
Soon to be announced will be proposals to conduct CER to answer a variety of ques-
ions regarding the best way to treat diseases and deliver health care. We have had the
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December 1, 2009:2200–1 President’s Pagepportunity to meet with the National Institutes of
ealth and Agency for Healthcare Research and Quality
irectors to gain some insight into how the process of
ER will go. It is clear that CER proposals will undergo
eer review and the usual critique that we are familiar
ith in the grant application process. So, like any grant
pplication, the projects must be focused, carefully
hought out, and well supported by literature review and,
ptimally, prior related research. The addition of over $1
illion to the research pool will provide many opportuni-
ies for obtaining research funding for these projects.
ith so many questions that arise in a typical clinical day
n cardiology, there is nearly an infinite number of com-
arisons of therapy that can be studied to improve prac-
ice efficiency and clinical outcomes.
ost
nd what about cost? Should we ignore all cost consider-
tions when deciding on tests or therapies for an individ-
al patient? Generally, we tend to ignore cost, and seek
he best therapy for each patient based on anticipated
linical benefit. But this concept cannot be extended to all
herapies. Cardiac transplant is an example. If an end-
tage heart failure patient is considered for transplant, the
ase must be presented to a committee of physicians,
urses, social workers, and financial representatives who
ust determine if the cost of the transplant is supported
y insurance and if the patient will be able to afford the
omplexity of medications needed after transplant. We
ave seen post-transplant patients die because they could
ot afford their medications and were too embarrassed to
sk for money to buy them. There are many situations in
edicine in which cost does become an issue in deciding
n therapy. With data from CER studies, both clinical
utcome and cost choices will be supported by data so
hat decisions can be better informed.We understand that health care is becoming unafford-
ble for many individuals and families. Spending excess
oney on care, therefore, does have an impact on others
ho are not covered when there are inadequate funds for
he collective health care of the country. We have a re-
ponsibility to be stewards of our health care system. This
ncludes being aware of excess costs when making deci-
ions on care, particularly when a high-cost test or proce-
ure has no incremental clinical benefit over other less
xpensive procedures.
My personal sense is that this kind of information will
mprove quality of care and efficiency, and if done well,
ill lower costs. It is essential that cost does not become
he principle focus of CER. Application of comparative
ffectiveness data should be through guidelines and prac-
ice standards that are carefully reviewed by a committee
f peers to be certain that the information is applied ap-
ropriately. The research is not expected to produce use-
ul information for 4 or 5 years. By then, many of us will
e using electronic information systems for day-to-day
atient care, and comparative effectiveness data, guide-
ines, and other information will be built into these sys-
ems to provide point-of-care decision tools to aid in pro-
iding high quality care.
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